Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine

Laura Y. McGirt, Kavitha Vasagar, Laura M. Gober, Sarbjit S Saini, Lisa A. Beck

Research output: Contribution to journalArticle

Abstract

Background: Antihistamines are the standard treatment for chronic idiopathic urticaria (CIU). For patients whose urticaria is unresponsive to antihistamines, the treatment options are limited. During the previous decade, there have been several case reports demonstrating success with sulfasalazine therapy. In this article, we present a case series evaluating sulfasalazine therapy for antihistamine-unresponsive CIU. Observations: Nineteen patients with antihistamine-unresponsive CIU were treated with sulfasalazine between 2002 and 2005. During sulfasalazine therapy, 14 patients (74%) reported significant improvement, 4 patients (21%) reported minimal improvement but were not satisfied with their symptom relief, and 1 patient (5%) reported a worsening of symptoms. Of the 13 patients who required systemic steroids to control their urticaria, all were able to reduce or discontinue steroid use during sulfasalazine therapy. Although 7 patients (37%) had adverse effects (eg, nausea, headache, mild or transient leukopenia, and transaminitis) that were thought to be caused by the use of sulfasalazine, they all kept taking the drug. Conclusions: This case series demonstrates that sulfasalazine can be a successful and safe treatment option for patients with CIU who have not responded adequately to treatment with antihistamines. Sulfasalazine was steroid sparing in all subjects who were steroid dependent.

Original languageEnglish (US)
Pages (from-to)1337-1342
Number of pages6
JournalArchives of Dermatology
Volume142
Issue number10
StatePublished - 2006

Fingerprint

Sulfasalazine
Urticaria
Histamine Antagonists
Steroids
Therapeutics
Leukopenia
Nausea
Headache

ASJC Scopus subject areas

  • Dermatology

Cite this

McGirt, L. Y., Vasagar, K., Gober, L. M., Saini, S. S., & Beck, L. A. (2006). Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Archives of Dermatology, 142(10), 1337-1342.

Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. / McGirt, Laura Y.; Vasagar, Kavitha; Gober, Laura M.; Saini, Sarbjit S; Beck, Lisa A.

In: Archives of Dermatology, Vol. 142, No. 10, 2006, p. 1337-1342.

Research output: Contribution to journalArticle

McGirt, LY, Vasagar, K, Gober, LM, Saini, SS & Beck, LA 2006, 'Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine', Archives of Dermatology, vol. 142, no. 10, pp. 1337-1342.
McGirt, Laura Y. ; Vasagar, Kavitha ; Gober, Laura M. ; Saini, Sarbjit S ; Beck, Lisa A. / Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. In: Archives of Dermatology. 2006 ; Vol. 142, No. 10. pp. 1337-1342.
@article{09946a0cf3cb4b2fbae7d5ec1882da77,
title = "Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine",
abstract = "Background: Antihistamines are the standard treatment for chronic idiopathic urticaria (CIU). For patients whose urticaria is unresponsive to antihistamines, the treatment options are limited. During the previous decade, there have been several case reports demonstrating success with sulfasalazine therapy. In this article, we present a case series evaluating sulfasalazine therapy for antihistamine-unresponsive CIU. Observations: Nineteen patients with antihistamine-unresponsive CIU were treated with sulfasalazine between 2002 and 2005. During sulfasalazine therapy, 14 patients (74{\%}) reported significant improvement, 4 patients (21{\%}) reported minimal improvement but were not satisfied with their symptom relief, and 1 patient (5{\%}) reported a worsening of symptoms. Of the 13 patients who required systemic steroids to control their urticaria, all were able to reduce or discontinue steroid use during sulfasalazine therapy. Although 7 patients (37{\%}) had adverse effects (eg, nausea, headache, mild or transient leukopenia, and transaminitis) that were thought to be caused by the use of sulfasalazine, they all kept taking the drug. Conclusions: This case series demonstrates that sulfasalazine can be a successful and safe treatment option for patients with CIU who have not responded adequately to treatment with antihistamines. Sulfasalazine was steroid sparing in all subjects who were steroid dependent.",
author = "McGirt, {Laura Y.} and Kavitha Vasagar and Gober, {Laura M.} and Saini, {Sarbjit S} and Beck, {Lisa A.}",
year = "2006",
language = "English (US)",
volume = "142",
pages = "1337--1342",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine

AU - McGirt, Laura Y.

AU - Vasagar, Kavitha

AU - Gober, Laura M.

AU - Saini, Sarbjit S

AU - Beck, Lisa A.

PY - 2006

Y1 - 2006

N2 - Background: Antihistamines are the standard treatment for chronic idiopathic urticaria (CIU). For patients whose urticaria is unresponsive to antihistamines, the treatment options are limited. During the previous decade, there have been several case reports demonstrating success with sulfasalazine therapy. In this article, we present a case series evaluating sulfasalazine therapy for antihistamine-unresponsive CIU. Observations: Nineteen patients with antihistamine-unresponsive CIU were treated with sulfasalazine between 2002 and 2005. During sulfasalazine therapy, 14 patients (74%) reported significant improvement, 4 patients (21%) reported minimal improvement but were not satisfied with their symptom relief, and 1 patient (5%) reported a worsening of symptoms. Of the 13 patients who required systemic steroids to control their urticaria, all were able to reduce or discontinue steroid use during sulfasalazine therapy. Although 7 patients (37%) had adverse effects (eg, nausea, headache, mild or transient leukopenia, and transaminitis) that were thought to be caused by the use of sulfasalazine, they all kept taking the drug. Conclusions: This case series demonstrates that sulfasalazine can be a successful and safe treatment option for patients with CIU who have not responded adequately to treatment with antihistamines. Sulfasalazine was steroid sparing in all subjects who were steroid dependent.

AB - Background: Antihistamines are the standard treatment for chronic idiopathic urticaria (CIU). For patients whose urticaria is unresponsive to antihistamines, the treatment options are limited. During the previous decade, there have been several case reports demonstrating success with sulfasalazine therapy. In this article, we present a case series evaluating sulfasalazine therapy for antihistamine-unresponsive CIU. Observations: Nineteen patients with antihistamine-unresponsive CIU were treated with sulfasalazine between 2002 and 2005. During sulfasalazine therapy, 14 patients (74%) reported significant improvement, 4 patients (21%) reported minimal improvement but were not satisfied with their symptom relief, and 1 patient (5%) reported a worsening of symptoms. Of the 13 patients who required systemic steroids to control their urticaria, all were able to reduce or discontinue steroid use during sulfasalazine therapy. Although 7 patients (37%) had adverse effects (eg, nausea, headache, mild or transient leukopenia, and transaminitis) that were thought to be caused by the use of sulfasalazine, they all kept taking the drug. Conclusions: This case series demonstrates that sulfasalazine can be a successful and safe treatment option for patients with CIU who have not responded adequately to treatment with antihistamines. Sulfasalazine was steroid sparing in all subjects who were steroid dependent.

UR - http://www.scopus.com/inward/record.url?scp=33750049299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750049299&partnerID=8YFLogxK

M3 - Article

C2 - 17043190

AN - SCOPUS:33750049299

VL - 142

SP - 1337

EP - 1342

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 10

ER -